RBD-specific polyclonal F(ab´)(2) fragments of equine antibodies in patients with moderate to severe COVID-19 disease: A randomized, multicenter, double-blind, placebo-controlled, adaptive phase 2/3 clinical trial

BACKGROUND: passive immunotherapy is a therapeutic alternative for patients with COVID-19. Equine polyclonal antibodies (EpAbs) could represent a source of scalable neutralizing antibodies against SARS-CoV-2. METHODS: we conducted a double-blind, randomized, placebo-controlled trial to assess effica...

Descripción completa

Detalles Bibliográficos
Autores principales: Lopardo, Gustavo, Belloso, Waldo H., Nannini, Esteban, Colonna, Mariana, Sanguineti, Santiago, Zylberman, Vanesa, Muñoz, Luciana, Dobarro, Martín, Lebersztein, Gabriel, Farina, Javier, Vidiella, Gabriela, Bertetti, Anselmo, Crudo, Favio, Alzogaray, Maria Fernanda, Barcelona, Laura, Teijeiro, Ricardo, Lambert, Sandra, Scublinsky, Darío, Iacono, Marisa, Stanek, Vanina, Solari, Rubén, Cruz, Pablo, Casas, Marcelo Martín, Abusamra, Lorena, Luciardi, Héctor Lucas, Cremona, Alberto, Caruso, Diego, de Miguel, Bernardo, Lloret, Santiago Perez, Millán, Susana, Kilstein, Yael, Pereiro, Ana, Sued, Omar, Cahn, Pedro, Spatz, Linus, Goldbaum, Fernando
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8037439/
https://www.ncbi.nlm.nih.gov/pubmed/33870149
http://dx.doi.org/10.1016/j.eclinm.2021.100843

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8037439/
https://www.ncbi.nlm.nih.gov/pubmed/33870149
http://dx.doi.org/10.1016/j.eclinm.2021.100843

Ejemplares similares